UCB Celltech

UCB Celltech is the UK-based biopharmaceutical research and development hub of the global pharmaceutical company UCB. Originally established in 1980 as Celltech, it was the UK's pioneer and largest biotechnology firm before being acquired by UCB in 2004 for approximately $2.7 billion. Operating out of Slough, Berkshire, UCB Celltech focuses on discovering and developing innovative antibody-based therapies for severe immunological and neurological conditions. The site leverages advanced automated antibody discovery platforms and fragment-based architectures to fuel UCB's global pipeline. Notable treatments developed or co-developed through its research include Cimzia for rheumatoid arthritis, Evenity for osteoporosis, and Bimzelx for plaque psoriasis.